S. Hossein Fatemi, M.D., Ph.D.

Professor, Department of Psychiatry
E-mail: fatem002@umn.edu

Clinical and Research Interests
Dr. Fatemi is the Associate Chair for Neuroscience and Translational Research for the Department of Psychiatry; the Bernstein Endowed Chair in Adult Psychiatry; Professor of Psychiatry, Neuroscience and Pharmacology, at the University of Minnesota Medical School. Dr. Fatemi’s research interests include the molecular causes and the biological basis of neurodevelopmental disorders, primarily schizophrenia and autism. His clinical interests include treatment and psychopharmacology of major depression, bipolar disorder, and schizophrenia. He has over 15 years experience in the treatment of psychiatric disorders. Dr. Fatemi is a member of the American College of Psychiatrists, a Fellow the American College of Neuropsychopharmacology, and International College of Neuropsychopharmacology, and a Distinguished Fellow of the American Psychiatric Association.

Education and Training

  • Residency in Psychiatry at University Hospitals, Cleveland, OH, 1992-1996
  • Intern in Diagnostic Radiology at Univ of Cincinnati Hospital, OH, 1991-1992
  • M.D. in Medicine, Case Western Reserve University, Cleveland, OH, 1991
  • Ph.D. in Anatomy, University of Nebraska Medical Center-Omaha, NE, 1979
  • M.S. in Anatomy, University of Nebraska Medical Center-Omaha, NE, 1978
  • B.S. in Biology, Baylor University, Waco, TX, 1974

Board Certification

  • Adult psychiatry, Diplomate of American Board of Psychiatry and Neurology
  • Pain medicine, Diplomate of the American Board of Psych. and Neurology
  • Psychosomatic medicine, Diplomate of American Board of Psych. and Neurology

Selected Publications:

(For a comprehensive list of recent publications, refer to PubMed, a service provided by the National Library of Medicine.)

Kneeland RE, Fatemi SH. Viral infection, inflammation and schizophrenia.
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012 (In
Press)

Folsom TD, Fatemi SH.  The Involvement of Reelin in Neurodevelopmental Disorders. Neuropharmacology, 2012, (In Press).

Fatemi SH, Folsom TD, Reutiman TJ, Novak J, Engel R. Comparative gene expression study of the chronic exposure to clozapine and haloperidol in rat frontal cortex.  Schizophrenia Research, 134:211-8, 2012.

Fatemi SH, Aldinger KA, Ashwood P, Bauman ML, Blaha CD, Blatt GJ, Chauhan A, Chauhan V, Dager SR, Dickson PE, Estes AM, Goldowitz D, Heck DH, Kemper TL, King BH, Martin LA, Millen KJ, Mittleman G, Mosconi MW, Persico AM, Sweeney JA, Webb SJ, Welsh JP. Consensus Paper: Pathological Role of the Cerebellum of Autism. Cerebellum, 11:777-807, 2012.

Fatemi SH, Folsom TD, Reutiman TJ, Novak J, Engel RH. Comparative gene expression study of the chronic exposure to clozapine and haloperidol in rat frontal cortex. Schizophr Res. 2011 Dec 9.

Fatemi SH, Folsom TD, Kneeland RE, Liesch SB. Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both Fragile X mental retardation protein and GABAA receptor beta 3 in adults with autism. Anat Rec (Hoboken). 2011 Oct;294(10):1635-45. doi: 10.1002/ar.21299.

Blatt GJ, Fatemi SH. Alterations in GABAergic biomarkers in the autism
brain: research findings and clinical implications. Anatomical Record, 294:1646-1652, 2011.

Fatemi SH, Folsom TD. Dysregulation of fragile × mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study. Mol Autism. 2011 May 6;2:6.

Fatemi SH, Folsom TD. The role of fragile X mental retardation protein in major mental disorders. Neuropharmacology. 2011 Jun;60(7-8):1221-6.

Fatemi SH, Folsom TD, Thuras PD. Deficits in GABA(B) receptor system in schizophrenia and mood disorders: a postmortem study. Schizophr Res. 2011 May;128(1-3):37-43.

Fatemi SH, Folsom TD, Rooney RJ, Mori S, Kornfield TE, Reutiman TJ, Kneeland RE, Liesch SB, Hua K, Hsu J, Patel DH. The viral theory of schizophrenia revisited: Abnormal placental gene expression and structural changes with lack of evidence for H1N1 viral presence in placentae of infected mice or brains of exposed offspring. Neuropharmacology. 2011 Jan 26.

Karkhane-Yousefi M, Folsom TD, Fatemi SH. A review of vareniclines’s efficacy and tolerability in smoking cessation studies in subjects with schizophrenia.  Journal of Addiction Research and Therapy, S4:3045, 2011.

Fatemi SH. Invited commentary: Reelin as a stress resilience factor in depression & psychosis. Neuropsychopharmacology, 36: 2371-2372, 2011.

Fatemi SH, Folsom TD, Reutiman TJ, Braun NN, Lavergne LG. Levels of phosphodiesterase 4A and 4B are altered by chronic treatment with psychotropic medications in rat frontal cortex. Synapse. 2010 Jul;64(7):550-5.

Fatemi SH, Reutiman TJ, Folsom TD, Rooney RJ, Patel DH, Thuras PD. mRNA and protein levels for GABAAalpha4, alpha5, beta1 and GABABR1 receptors are altered in brains from subjects with autism. J Autism Dev Disord. 2010 Jun;40(6):743-50.

Fatemi SH, Reutiman TJ, Folsom TD. The role of lithium in modulation of brain genes: relevance for aetiology and treatment of bipolar disorder. Biochem Soc Trans. 2009 Oct;37(Pt 5):1090-5.

Fatemi SH, Folsom TD, Reutiman TJ, Huang H, Oishi K, Mori S. Prenatal viral infection of mice at E16 causes changes in gene expression in hippocampi of the offspring. Eur Neuropsychopharmacol. 2009 Sep;19(9):648-53.

Fatemi SH. Potential microbial origins of schizophrenia and their treatments. Drugs Today (Barc). 2009 Apr;45(4):305-18.

Fatemi SH, Folsom TD, Reutiman TJ, Abu-Odeh D, Mori S, Huang H, Oishi K. Abnormal expression of myelination genes and alterations in white matter fractional anisotropy following prenatal viral influenza infection at E16 in mice. Schizophr Res. 2009 Jul;112(1-3):46-53. Epub 2009 May 31.

Fatemi SH, Reutiman TJ, Folsom TD. Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats. Schizophr Res. 2009 Jun;111(1-3):138-52.